- Home
- / Alder BioPharmaceuticals
Alder BioPharmaceuticals
Alder BioPharmaceuticals Summary
Company Summary
- Overview
- Alder BioPharmaceuticals is a biopharmaceutical company that discovers, develops, and seeks to commercialize genetically engineered therapeutic antibodies. Its lead product candidate, eptinezumab, is being evaluated for migraine prevention. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.
- Type
- Subsidiary
- Status
- Closed
- Founded
- 2004
- HQ
- Bothell, WA, US | view all locations
- Website
- http://www.alderbio.com
- Cybersecurity rating
- Sectors
Table of Contents
Key People
Larry Benedict, Vice President, Finance
Mark Litton, Chief Business Officer and Treasurer
Paul Cleveland, Interim President and Chief Executive Officer
LocationsView all
1 location detected
Bothell, WA HQ
United States
11804 North Creek Pkwy
Alder BioPharmaceuticals Financials
Summary Financials
- Net income (Q2, 2019)
- ($58.4M)
- Cash (Q2, 2019)
- $88.4M
- EBIT (Q2, 2019)
- ($55.8M)